Recent News

• 08.12.2026 - CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation
• 06.08.2026 - CNS Pharmaceuticals CFO, Steve O’Loughlin, Highlights Company’s Recent $22.5M Financing in Virtual Investor “What This Means” Segment
• 05.20.2026 - CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company’s Recent Strategic Transformation Progress
• 05.20.2024 - CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase
• 05.16.2024 - CNS Pharmaceuticals Reports First Quarter 2024 Financial Results
• 04.23.2024 - CNS Pharmaceuticals to Present at the LSX World Congress 2024
• 04.22.2024 - CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity
• 04.01.2024 - CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements
• 04.01.2024 - CNS Pharmaceuticals to Present at Two Investor Conferences in April
• 01.30.2024 - CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering

Recent Filings

• 08.12.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.02.2026 - 8-K Current report
• 07.02.2026 - EX-99.1 EX-99.1
• 05.26.2026 - 424B3 Prospectus [Rule 424(b)(3)]
• 05.26.2026 - EFFECT Notice of Effectiveness
• 05.22.2026 - CORRESP Correspondence
• 05.22.2026 - UPLOAD SEC-generated letter
• 05.20.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.19.2026 - D Notice of Exempt Offering of Securities
• 05.19.2026 - S-3 Registration statement under Securities Act of 1933